New drug YA-101 aims to slow rare brain disease
Disease control
Recruiting now
This Phase 2 trial tests the safety and effectiveness of YA-101, an oral drug, in 75 people with multiple system atrophy (MSA), a rare and progressive brain disorder. Participants will receive either YA-101 or a placebo twice daily for several weeks. The study will monitor side e…
Phase: PHASE2 • Sponsor: Dasher Neuroscience Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC